Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at Chardan Capital

Lexeo Therapeutics (NASDAQ:LXEO)‘s stock had its “buy” rating reissued by investment analysts at Chardan Capital in a report released on Tuesday,Benzinga reports. They presently have a $25.00 price objective on the stock.

A number of other brokerages also recently issued reports on LXEO. Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. Leerink Partners decreased their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $23.60.

Lexeo Therapeutics Stock Up 50.9 %

Lexeo Therapeutics stock opened at $4.09 on Tuesday. The firm has a 50 day simple moving average of $4.15 and a 200 day simple moving average of $6.71. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.50. The firm has a market capitalization of $135.24 million, a price-to-earnings ratio of -1.29 and a beta of 3.85.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.09. On average, analysts predict that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Institutional Trading of Lexeo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Allostery Investments LP purchased a new position in Lexeo Therapeutics in the fourth quarter worth $33,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Lexeo Therapeutics in the 4th quarter worth about $46,000. BNP Paribas Financial Markets lifted its position in Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in Lexeo Therapeutics in the fourth quarter worth approximately $69,000. Finally, SG Americas Securities LLC bought a new position in Lexeo Therapeutics during the fourth quarter valued at approximately $72,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.